Form 4: OraSure Director Steven Kyle Boyd Receives Stock Grant

Director Steven Kyle Boyd was granted 46,106 restricted shares of OraSure Technologies as part of the company's annual equity compensation plan.

Summary

• Steven Kyle Boyd, a member of the Board of Directors, received a grant of 46,106 restricted shares of common stock on June 3, 2026.
• The shares were granted at no cost as part of the OraSure Technologies, Inc. Stock Award Plan.
• Following this transaction, the reporting person directly owns 159,568 shares of the company.
• The restricted shares are scheduled to vest in full on the earlier of June 3, 2027, or the date of the 2027 Annual Meeting of Stockholders.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event, as it confirms continued insider commitment and aligns management interests with shareholders without indicating any immediate market volatility.

Positives

• Increased insider ownership by approximately 40.6% for this specific director.
• Equity-based compensation aligns the interests of the Board of Directors with those of the shareholders.
• The vesting period encourages long-term commitment to the company's governance.

Negatives

• The grant represents a non-cash expense to the company that contributes to share dilution.

Risks

• Vesting is contingent upon continued service; if the director voluntarily leaves the board before June 2027, the shares will be forfeited.

Future Outlook

The director's equity stake is set to vest fully by mid-2027, assuming continued service on the board, indicating a stable governance outlook for the coming year.

Management Comments

• Vesting shall cease immediately if the named individual voluntarily ceases to serve as a member of the Board of Directors.

Industry Context

StockSavvy.ai notes that OraSure's use of restricted stock for director compensation is consistent with industry standards in the healthcare and diagnostics sector, where equity is used to attract and retain qualified board members while preserving cash.

Comparison to Industry Standards

• The grant size is comparable to mid-cap medical device and diagnostic peers such as QuidelOrtho and Meridian Bioscience.
• One-year cliff vesting is a standard duration for annual director equity awards in the NASDAQ-listed healthcare space.

Corporate Governance

Related Party Transactions

• The issuance of stock to a director under an approved incentive plan is a standard related-party transaction for compensation purposes.

Stakeholder Impact

• Shareholders may experience minor dilution from the issuance of new shares.
• The Board of Directors maintains stability through equity-linked retention.

Next Steps

• Vesting of the 46,106 shares on or before the 2027 Annual Meeting of Stockholders.

Key Dates

Recommendation

This filing represents a routine administrative compensation event for a director and does not provide new material information regarding the company's operational performance or financial health that would warrant a change in investment rating.

Keywords

OraSure Technologies, OSUR, Insider Trading, Form 4, Restricted Stock Units, Director Compensation, Medical Diagnostics, Equity Grant